1. Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry
- Author
-
V. Torrente-Segarra, Elena Aurrecoechea, Javier Narváez, Tomas R. Vazquez-Rodriguez, José Luis Andreu-Sánchez, Clara Moriano Morales, Gema Bonilla, Eva Tomero, José Luis Marenco de la Fuente, Esther Uriarte-Isacelay, Alejandro Olivé-Marqués, José M. Pego-Reigosa, Eva Salgado, José Antonio Bernal-Vidal, Cristina Bohórquez, Claudia Stoye, Paloma García de la Peña, Tatiana Cobo-Ibáñez, Jose A Bernal-Vidal, Natalia Mena-Vázquez, María José Galindo, Esteban Salas-Heredia, Joan Calvet, Carlos Montilla, Javier Manero-Ruiz, M J García-Villanueva, Mercedes Freire, Ana Melissa-Anzola, Nuria Lozano-Rivas, Antonio Fernández-Nebro, Iñigo Rúa-Figueroa, Lorena Expósito, María Esther Ruiz-Lucea, Francisco Javier Toyos, Elia Vals, Francisco Javier Novoa, Ricardo Blanco, and Mónica Ibáñez-Barcelo
- Subjects
Male ,sistema de registros ,Autoimmune diseases ,humanos ,enfermedades autoinmunes ,Autoimmunity ,autoinmunidad ,0302 clinical medicine ,Mixed connective tissue disease ,systemic lupus erythematosus ,immune system diseases ,hidroxicloroquina ,Medicine ,Lupus Erythematosus, Systemic ,Pharmacology (medical) ,Registries ,skin and connective tissue diseases ,mediana edad ,AcademicSubjects/MED00360 ,Systemic lupus erythematosus ,Malalties autoimmunitàries ,adulto ,Middle Aged ,Clinical Science ,humanities ,adulto joven ,Antirheumatic Agents ,Female ,antirreumáticos ,Hydroxychloroquine ,Adult ,medicine.medical_specialty ,polyautoimmunity ,Autoimmune Diseases ,Autoimmune thyroiditis ,03 medical and health sciences ,Young Adult ,Rheumatology ,Internal medicine ,Humans ,030203 arthritis & rheumatology ,Autoimmune disease ,Lupus erythematosus ,business.industry ,Autoantibody ,Odds ratio ,multiple autoimmune syndrome, polyautoimmunity, systemic lupus erythematosus ,medicine.disease ,body regions ,Cross-Sectional Studies ,Lupus eritematós ,multiple autoimmune syndrome ,business ,030215 immunology ,estudios transversales - Abstract
Objectives. This article estimates the frequency of polyautoimmunity and associated factors in a large retrospective cohort of patients with SLE. Methods. RELESSER (Spanish Society of Rheumatology Lupus Registry) is a nationwide multicentre, hospital-based registry of SLE patients. This is a cross-sectional study. The main variable was polyautoimmunity, which was defined as the co-occurrence of SLE and another autoimmune disease, such as autoimmune thyroiditis, RA, scleroderma, inflammatory myopathy and MCTD. We also recorded the presence of multiple autoimmune syndrome, secondary SS, secondary APS and a family history of autoimmune disease. Multiple logistic regression analysis was performed to investigate possible risk factors for polyautoimmunity. Results. Of the 3679 patients who fulfilled the criteria for SLE, 502 (13.6%) had polyautoimmunity. The most frequent types were autoimmune thyroiditis (7.9%), other systemic autoimmune diseases (6.2%), secondary SS (14.1%) and secondary APS (13.7%). Multiple autoimmune syndrome accounted for 10.2% of all cases of polyautoimmunity. A family history was recorded in 11.8%. According to the multivariate analysis, the factors associated with polyautoimmunity were female sex [odds ratio (95% CI), 1.72 (1.07, 2.72)], RP [1.63 (1.29, 2.05)], interstitial lung disease [3.35 (1.84, 6.01)], Jaccoud arthropathy [1.92 (1.40, 2.63)], anti-Ro/SSA and/or anti-La/SSB autoantibodies [2.03 (1.55, 2.67)], anti-RNP antibodies [1.48 (1.16, 1.90)], MTX [1.67 (1.26, 2.18)] and antimalarial drugs [0.50 (0.38, 0.67)]. Conclusion. Patients with SLE frequently present polyautoimmunity. We observed clinical and analytical characteristics associated with polyautoimmunity. Our finding that antimalarial drugs protected against polyautoimmunity should be verified in future studies., The RELESSER Registry was partially funded by GlaxoSmithKline (GSK), Roche, Union Chimique Belge (UCB), Lilly and Novartis. The sponsors had no role in the study design, data collection, analysis or interpretation, in writing the report, or in the decision to submit the article for publication. J.M.P.-R. is supported by grant 316265 (BIOCAPS) from the European Union 7th Framework Program (FP7/REGPOT-2012-2013.1). The study was supported by FIS Grant PI11/02857 (Instituto Carlos III, Fondos FEDER). Grant for medical researchers of the 'Fundacion Espanola de Reumatologia'.
- Published
- 2019